Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ropinirole Immediate Release · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Ropinirole | EXPERIMENTAL | single dose .25mg of IR formulation, .05mg of RLS controlled release |
| Name | Type | Description |
|---|---|---|
| Ropinirole Immediate Release | DRUG | Ropinirole Immediate Release |
Inclusion Criteria: * Adolescent subjects diagnosed with probable or definite Restless Leg Syndrome (RLS). Exclusion Criteria: * Subjects who require RLS treatment during the daytime, suffer from other primary sleep disorders or are taking medication known to induce drowsiness, affect RLS or slee...
Ropinirole Immediate Release is a small molecule being studied for Restless Legs Syndrome, a neurological condition that causes an urge to move the legs. The Phase 1 trial NCT00140712 evaluated ropinirole tablets in young patients with Restless Legs Syndrome across the United States, Belgium, and France.
Ropinirole Immediate Release targets the dopamine receptors DRD2, DRD3, and DRD4, where it acts as an agonist. By activating these receptors, the drug is designed to influence dopamine signaling relevant to Restless Legs Syndrome. This receptor agonist activity is the basis for its development in Neurology.
Ropinirole Immediate Release is developed by GSK plc, which trades under the ticker GSK. The company is the sponsor behind the clinical development of this small molecule for Restless Legs Syndrome.
Ropinirole Immediate Release is in Phase 1 development. It is investigational and has not been approved by the FDA. One Phase 1 trial, NCT00140712, has been completed, and no trials are currently active.
Ropinirole Immediate Release has been studied in one completed Phase 1 trial, NCT00140712, titled Ropinirole Tablets In Young Patients With Restless Legs Syndrome. The trial enrolled 9 patients aged 12 years and older in the United States, Belgium, and France. It was an uncontrolled study without randomization or double blinding.